XML 30 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jan. 01, 2018
Mar. 31, 2018
Mar. 31, 2017
Dec. 31, 2017
Aug. 31, 2014
Property, Plant and Equipment [Line Items]          
Unrealized gains on equity investments   $ 0 $ (66)    
Decrease in accumulated deficit   (327,400)   $ (400,924)  
Revenues   56,157 29,267    
Milestone payment received   4,600      
Third-party in-licensor portion of milestone payment received   3,000      
Net revenue from milestone method revenue   1,600      
Operating income (loss)   37,041 10,216    
Gain (loss) from Viking   $ 21,097 $ (1,083)    
Outstanding warrants to purchase shares of Viking's common stock (shares)         3,264,643
Warrant exercise price (USD per share)         $ 125.08
Viking Therapeutics, Inc.          
Property, Plant and Equipment [Line Items]          
Equity method investment, ownership (percent)   12.40%      
Market value of investment in Viking   $ 27,500      
Outstanding warrants to purchase shares of Viking's common stock (shares)   1,500,000      
Warrant exercise price (USD per share)   $ 1.50      
Recurring          
Property, Plant and Equipment [Line Items]          
Assets, fair value   $ 249,335   188,764  
Recurring | Investment in Warrants          
Property, Plant and Equipment [Line Items]          
Assets, fair value   4,594   3,846  
Recurring | Note Receivable - Viking Therapeutics          
Property, Plant and Equipment [Line Items]          
Assets, fair value   3,877   3,877  
Recurring | Level 1          
Property, Plant and Equipment [Line Items]          
Assets, fair value   33,886   5,742  
Recurring | Level 1 | Investment in Warrants          
Property, Plant and Equipment [Line Items]          
Assets, fair value   $ 4,594   3,846  
Recurring | Level 1 | Note Receivable - Viking Therapeutics          
Property, Plant and Equipment [Line Items]          
Note receivable, stated interest rate (as a percent)   2.50%      
Assets, fair value   $ 0   0  
Recurring | Level 3          
Property, Plant and Equipment [Line Items]          
Assets, fair value   3,877   3,877  
Recurring | Level 3 | Investment in Warrants          
Property, Plant and Equipment [Line Items]          
Assets, fair value   0   0  
Recurring | Level 3 | Note Receivable - Viking Therapeutics          
Property, Plant and Equipment [Line Items]          
Assets, fair value   $ 3,877   $ 3,877  
Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606          
Property, Plant and Equipment [Line Items]          
Decrease in accumulated deficit $ 25,400        
Revenues (11,900)        
Operating income (loss) (11,900)        
Accumulated Other Comprehensive Income | Accounting Standards Update 2016-01          
Property, Plant and Equipment [Line Items]          
Unrealized gains on equity investments (2,600)        
Retained Earnings | Accounting Standards Update 2016-01          
Property, Plant and Equipment [Line Items]          
Unrealized gains on equity investments $ 2,000        
Royalty Agreements | Aziyo          
Property, Plant and Equipment [Line Items]          
Effective interest rate for forecasted cash flows (as a percent)   26.00%